Prometheus, Mayo Collaborative Services Inc. diagnostic news

The U.S. Supreme Court ruled 9-0 that two patents from Prometheus on the use of biomarkers to help determine a patient's treatment are not eligible for patenting under Section 101 of the Patent Act. The court said in its opinion the claimed methods for measuring metabolites to optimize dosing of a drug are not sufficient to transform unpatentable natural correlations into patentable applications of those correlations. ...